Industry expert Kunal Jaiswal to head strategic development for Catalent's clinical supply services business
Will lead the company’s ongoing efforts to anticipate and act upon industry trends and technologies that may affect study sponsors, clinical sites, and patients, and to inform the development and delivery of current and future clinical supply services.
Catalent Pharma Solutions has appointed Kunal Jaiswal to the role of Vice President, Strategic Development Solutions, Clinical Supply Services. In his role, Mr Jaiswal will lead the company’s ongoing efforts to anticipate and act upon industry trends and technologies that may affect study sponsors, clinical sites, and patients, and to inform the development and delivery of current and future clinical supply services.
Mr Jaiswal brings moe than 10 years of clinical supply chain operations experience. Most recently, he was Director of Clinical Supply Packaging Operations at Pfizer with a prior engagement at Merck as Head of Supply Chain Strategy. Mr Jaiswal is a recognized industry expert and former Chair of the ISPE’s (International Society for Pharmaceutical Engineering) Investigational Products Steering Committee. He holds a Bachelor’s degree in pharmacy from Purdue University and a Master’s in business administration from Western Michigan University.
“Kunal is an important addition to our leadership team that will accelerate our ongoing efforts to develop and deliver industry-leading clinical supply solutions to our customers,” stated Wetteny Joseph, President of Catalent Clinical Supply Services. “His extensive experience brings our team a wealth of knowledge and unique customer perspective that will enable the next generation of clinical trial innovation in our industry.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.